Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum Resistant High Grade Epithelial Ovarian Cancer”

68 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 68 results

Early research (Phase 1)Ended earlyNCT04893551
What this trial is testing

Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants

Who this might be right for
Ovarian Neoplasms
BerGenBio ASA 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Ended earlyNCT03610490
What this trial is testing

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Who this might be right for
Malignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Ovarian Carcinoma+9 more
M.D. Anderson Cancer Center 16
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)WithdrawnNCT02948101
What this trial is testing

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT04718675
What this trial is testing

KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)

Who this might be right for
Relapsed Solid TumorsRefractory Solid TumorsNon-Hodgkin Lymphoma+2 more
Kronos Bio 135
Early research (Phase 1)Active Not RecruitingNCT01883297
What this trial is testing

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
RecurrentPlatinum-resistantHigh Grade Serous Ovarian Cancer+2 more
University Health Network, Toronto 3
Testing effectiveness (Phase 2)Looking for participantsNCT06906341
What this trial is testing

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms+1 more
Corcept Therapeutics 270
Large-scale testing (Phase 3)Looking for participantsNCT05281471
What this trial is testing

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Who this might be right for
Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerFallopian Tube Cancer+4 more
Genelux Corporation 186
Large-scale testing (Phase 3)Ended earlyNCT04729387
What this trial is testing

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Who this might be right for
Ovarian Cancer
Novartis Pharmaceuticals 358
Large-scale testing (Phase 3)Ended earlyNCT04729608
What this trial is testing

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Who this might be right for
Platinum-resistant Ovarian Cancer
Aravive, Inc. 366
Testing effectiveness (Phase 2)Study completedNCT03648489
What this trial is testing

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Who this might be right for
Ovarian CancerOvarian NeoplasmsOvarian Carcinosarcoma+7 more
Imperial College London 134
Large-scale testing (Phase 3)Looking for participantsNCT06161025
What this trial is testing

Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Solid Cancer
Daiichi Sankyo 860
Testing effectiveness (Phase 2)Study completedNCT05613088
What this trial is testing

MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Neoplasms, Ovarian
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)Active Not RecruitingNCT03449108
What this trial is testing

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaDedifferentiated ChondrosarcomaGiant Cell Tumor of Bone+13 more
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05271318
What this trial is testing

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Who this might be right for
Platinum-refractory Ovarian CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+6 more
TILT Biotherapeutics Ltd. 29
Testing effectiveness (Phase 2)Looking for participantsNCT04518501
What this trial is testing

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Who this might be right for
Efficacy and Safety
Xing Xie 50
Testing effectiveness (Phase 2)Study completedNCT03268382
What this trial is testing

P53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Who this might be right for
High-grade Serous Ovarian Cancer
Aprea Therapeutics 36
Testing effectiveness (Phase 2)Study completedNCT02489903
What this trial is testing

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Who this might be right for
Small Cell CarcinomaCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors+1 more
EpicentRx, Inc. 139
Next Page